Primary source: Guidance and regulation
The MHRA has confirmed the regulatory classification of microbiome-based medicinal products under the existing framework and provided specific guidance on safety assessments, product characterization, and suggested early engagement with their Innovation Office.
This guidance allows developers of microbiome therapies to understand the expectations for compliance including safety assessments for AMR risks and supports effective planning in navigating the licensing process, which can significantly impact development timelines and regulatory success.
Developers of MBMPs must align their safety assessment protocols with the MHRA's expectations and are encouraged to engage with the MHRA early to establish appropriate regulatory strategies.
Regulatory Intelligence Lead
Review in the next regulatory intelligence cycle.
Clarifies that MBMPs are regulated as biological medicinal products or ATMPs under existing frameworks. Sets specific expectations for developers regarding product characterization, manufacturing consistency, and safety assessments for antimicrobial resistance (AMR) risk. Reaffirms that faecal microbiota transplantation (FMT) remains under the 'specials' or clinical trial routes for specific indications.
Developers of microbiome therapies must align their safety assessment protocols with the MHRA's expectations for antimicrobial resistance risk and batch-to-batch variability. Early engagement with the MHRA Innovation Office or Scientific Advice is recommended to de-risk development and agree on proportionate safety monitoring and clinical evidence strategies.
Developers of MBMPs must align their safety assessment protocols with the MHRA's expectations and are encouraged to engage with the MHRA early to establish appropriate regulatory strategies.
The Medicines and Healthcare products Regulatory Agency (MHRA) has published a position paper providing clarity on the regulatory and licensing pathways for microbiome-based medicinal products (MBMPs) in the UK. It specifies that MBMPs are regulated under the Human Medicines Regulations 2012 and may be classified as biological medicinal products or advanced therapy medicinal products (ATMPs). The document emphasizes essential aspects such as product characterization, safety assessments including antimicrobial resistance (AMR) risks, and the generation of clinical evidence necessary for gaining licenses. Furthermore, it stresses the importance of early engagement with the MHRA for developers.
What changed: The MHRA has confirmed the regulatory classification of microbiome-based medicinal products under the existing framework and provided specific guidance on safety assessments, product characterization, and suggested early engagement with their Innovation Office.
Why it matters: This guidance allows developers of microbiome therapies to understand the expectations for compliance including safety assessments for AMR risks and supports effective planning in navigating the licensing process, which can significantly impact development timelines and regulatory success.
Practical implication: Developers of MBMPs must align their safety assessment protocols with the MHRA's expectations and are encouraged to engage with the MHRA early to establish appropriate regulatory strategies.
Published from the Firecrawl policy change extraction pipeline.
Implement a gap analysis for 505(b)(2) applications to identify safety data needs and adjust safety monitoring systems as necessary to accommodate new product characteristics.
MAHs and sponsors must enhance their pharmacovigilance systems to monitor microbiome-specific safety issues, comply with established safety standards, and address concerns related to antimicrobial resistance.
Stakeholders, including manufacturers and clinicians, must review and potentially revise their post-market vigilance and safety monitoring protocols in response to the FDA's proposed regulatory approaches for generative AI devices.
Clinical safety and pharmacovigilance teams should review the FDA guidance and adjust their monitoring plans to ensure they align with the newly provided recommendations regarding safety endpoints and data collection processes.
